Metabolic Signaling
AOD-9604
HGH Fragment 176-191
AOD-9604 (HGH Fragment 176-191)
Research context
AOD-9604 corresponds to residues 176–191 of human growth hormone with an added N-terminal tyrosine. Research examines lipolytic activity in adipocyte preparations independent of the growth-promoting activity associated with the full-length hormone.
Common assays: Adipocyte lipolysis quantification · Glycerol release · Receptor binding characterisation
Specification
| Designation | HGH Fragment 176-191 |
|---|---|
| Full name | AOD-9604 (HGH Fragment 176-191) |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| CAS number | 221231-10-3 |
| Molecular formula | C78H123N23O23S2 |
| Molecular weight | 1815.08 g/mol |
| Formats | 10 mL Vial |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Regulatory status | Not an approved drug. Withdrawn from FDA 503A Category 2 in 2024; the advisory committee voted against adding it to the 503A bulks list in late 2024. 2026 status by compound → |
| Current lot | AOD10VAS0426 → |
AOD-9604 COA: certificates of analysis by lot
One lot of AOD-9604 has a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| AOD10VAS0426 | 10 mg Vial | >99.4% | 2026-05-11 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Heffernan M, Summers RJ, Thorburn A, et al.The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3 AR knock-out miceEndocrinology · 2001 Find on PubMed ↗
Common questions
How does AOD-9604 differ from full-length growth hormone?
It comprises only residues 176–191 plus an added tyrosine, and lacks the regions associated with growth-promoting and insulin-antagonistic activity in published characterisation.
Where can I see the AOD-9604 certificate of analysis?
Every published AOD-9604 lot has its own certificate page on this site, listed under "AOD-9604 COA" above. There is one published lot; the most recent, lot AOD10VAS0426, was reported on 2026-05-11 at >99.4% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
GLP-1S
GLP-1 receptor agonist
A long-acting glucagon-like peptide-1 receptor agonist studied in incretin signalling research.
GLP-2T Dual Agonist
Dual GIP/GLP-1 receptor agonist
A synthetic dual agonist at both GIP and GLP-1 receptors, studied in comparative incretin signalling.
GLP-3R Triple Agonist
Triple GLP-1/GIP/glucagon receptor agonist
A synthetic triple agonist at GLP-1, GIP and glucagon receptors, studied in multi-receptor incretin research.
GLP-3R / GLP-1S Agonist Blend
Dual agonist blend
A prepared blend combining a triple receptor agonist and a GLP-1 receptor agonist in a single metered format.